MYCN and neuroblastoma: We therefore conclude that chimeric co-amplification of proto-oncogenes partly explains the malignant phenotype of neuroblastomas with complex MYCN amplicons, whereas enhancer hijacking in class II amplicons does not change clinical behavior, fully phenocopying class I MYCN amplicons.